Creabilis Therapeutics S.p.a.

Cecilia Oderda

Valentina Mainero

Chiara Lorenzetto

Silvio Traversa

Silvano Fumero

Luca Beccaria

Domenico Barone

Luisa Bertarione Rava Rossa

Carlo Pincelli

Alessandra Marconi

Raffaella Bagnod

The present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. The invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of a) neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system; b) dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis; and c) NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula (I).

Polymer conjugates of K-252A and derivatives thereof

Growing community of inventors

Vésenaz, Switzerland

Cecilia Oderda